前列腺腺癌伴神经内分泌分化:18F-FDG PET/CT与68Ga-DOTANOC PET/CT相对于68Ga-PSMA PET/CT的潜在用途
本文讨论一名67岁男性前列腺腺癌伴神经内分泌分化患者,其肿瘤表达生长抑素受体而非前列腺特异性膜抗原,因此68Ga-PSMA PET/CT显像存在潜在缺陷,而68Ga-DOTANOC PET/CT和18F-FDG PET/CT在此类病例中可能有助于指导治疗。
要点
- 部分前列腺癌患者存在神经内分泌分化,表达生长抑素受体而非PSMA。
- 此类病例中68Ga-PSMA PET/CT显像可能存在潜在缺陷。
- 68Ga-DOTANOC PET/CT和18F-FDG PET/CT在此类病例中可能有助于指导治疗。
核心结论
- 对于前列腺腺癌伴神经内分泌分化的患者,68Ga-PSMA PET/CT显像存在潜在缺陷,而68Ga-DOTANOC PET/CT和18F-FDG PET/CT可能有助于指导治疗。
研究设计与样本
- 本文为病例报告,讨论一名67岁男性前列腺腺癌伴神经内分泌分化患者。
主要发现
- 该患者肿瘤表达生长抑素受体而非前列腺特异性膜抗原,68Ga-PSMA PET/CT显像存在潜在缺陷。
- 68Ga-DOTANOC PET/CT和18F-FDG PET/CT在此类病例中可能有助于指导治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ga-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like Ga-DOTANOC PET/CT and F-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of Ga-PSMA PET/CT imaging and benefit of Ga-DOTANOC PET/CT and F-FDG PET/CT in such cases.
引用
- Parida GK, Tripathy S, Datta Gupta S, et al. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT. Clin Nucl Med. 2018. PMID: 29474196. doi:10.1097/RLU.0000000000002013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。